Q: Please, your analysis for Biorem, thanks.
5i Research Answer:
Due to its tiny size we do not follow BRM too closely. Risks are very high with any company with a market cap less than $35M. But, it is better than most microcaps. Sales are growing, it has a strong balance sheet, is profitable and cash flow is positive. Valuation at 12X earnings is good. The last quarter was good and it is buying back shares. Its backlog looks good for some short term visibility of revenue. Sales rose 29% in the Q2 and the backlog rose from $57M to $61M. It looks very good for a microcap, but keep in mind the very high risk level overall here.